Combination Therapy with Repatha (Evolocumab) and Ezetimibe
The combination of evolocumab (Repatha) and ezetimibe is FDA-approved, safe, and highly effective for LDL-C reduction in patients requiring intensive lipid-lowering therapy. Both medications work through complementary mechanisms and can be used together without dose adjustments or significant drug interactions 1, 2.
Dosing Recommendations
Evolocumab (Repatha) Dosing
- Standard dose: 140 mg subcutaneously every 2 weeks OR 420 mg subcutaneously once monthly 2
- Both dosing regimens provide equivalent LDL-C reduction (58-64% additional reduction when added to statin therapy) 1
- If switching between regimens, administer the first dose of the new regimen on the next scheduled date of the prior regimen 2
- Administration sites: Abdomen, thigh, or upper arm; rotate injection sites 1, 2
- Allow medication to warm to room temperature for at least 30 minutes before injection 2
Ezetimibe Dosing
- Standard dose: 10 mg orally once daily, with or without food 1
- Provides approximately 18% LDL-C reduction as monotherapy, or 25% incremental reduction when added to statin 3
Combined Therapy
No dose adjustments are needed when using evolocumab and ezetimibe together 1. The 2022 ACC Expert Consensus explicitly states that evolocumab is FDA-approved for use "alone or in combination with other lipid-lowering therapies" including ezetimibe 1.
Expected Efficacy
When both agents are added to maximally tolerated statin therapy:
- Ezetimibe alone: Additional 25% LDL-C reduction 3
- Evolocumab alone: Additional 58-64% LDL-C reduction 1
- Triple therapy (statin + ezetimibe + evolocumab): Can achieve LDL-C reductions exceeding 70% from baseline 4
The 2024 International Lipid Expert Panel recommends this stepwise approach: start with high-intensity statin, add ezetimibe if LDL-C remains >55 mg/dL (1.4 mmol/L) after 4-6 weeks, then add PCSK9 inhibitor if target still not achieved after another 4-6 weeks 5.
Safety Profile
Evolocumab Safety
Common adverse effects (>5% and more frequent than placebo) 2:
- Nasopharyngitis
- Upper respiratory tract infection
- Influenza
- Back pain
- Injection site reactions (2.1% vs 1.6% with placebo)
Important considerations:
- No evidence of increased cognitive adverse effects in FOURIER or EBBINGHAUS trials 1, 3
- Serious adverse events similar to placebo 6
- Latex sensitivity: Some presentations contain dry natural rubber in needle cover; latex-free options available 1, 2
Ezetimibe Safety
Common adverse effects 1:
- Nasopharyngitis
- Upper respiratory tract infection
- Arthralgia
- Diarrhea
- Cyclosporine
- Fibrates
- Bile acid sequestrants (take ezetimibe ≥2 hours before or ≥4 hours after bile acid sequestrants)
Combined Safety
No clinically significant drug-drug interactions exist between evolocumab and ezetimibe 3. The combination is well-tolerated with no additive adverse effects 1. Both medications have demonstrated cardiovascular outcome benefits: FOURIER trial for evolocumab (15% relative risk reduction in major adverse cardiovascular events) 1, 6 and IMPROVE-IT trial for ezetimibe 1.
Monitoring
- Assess LDL-C as early as 4 weeks after initiating evolocumab 2
- For monthly evolocumab dosing, measure LDL-C just prior to the next scheduled dose, as levels can vary during the dosing interval 2
- Monitor for hypersensitivity reactions with evolocumab (angioedema has occurred); discontinue if serious reactions develop 2
- No routine laboratory monitoring required for either medication beyond lipid panels
Clinical Pitfalls to Avoid
Don't delay PCSK9 inhibitor addition: If on maximally tolerated statin plus ezetimibe and LDL-C remains >55 mg/dL (1.4 mmol/L) in very high-risk patients, add evolocumab promptly 5, 7
Latex allergy: Prescribe latex-free presentations of Repatha for latex-sensitive patients 1, 2
Missed doses: If evolocumab dose missed within 7 days, take immediately and resume schedule; if >7 days for every-2-week dosing, wait until next scheduled dose 2
Storage: Refrigerate but allow to reach room temperature before injection to minimize injection site reactions 2